Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCVS Caremark Spravato Prior Auth Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentCVS CaremarkPolicy 2889-A

    Specialty Guideline Management Spravato

    Customize your policy alerts

    Sign up for cvs_caremark Policy 2889-A alerts

    Get alerted when Policy 2889-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and continuation coverage for Spravato (esketamine) in adults with treatment-resistant depression or major depressive disorder with acute suicidal ideation or behavior, subject to clinical criteria, documentation, provider supervision, monitoring, and REMS-compliant administration.

    Policy Summary
    PayerCVS Caremark
    PolicySpecialty Guideline Management Spravato
    Policy CodePolicy 2889-A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization requests with the required pretreatment or current standardized depression severity scores.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    18+Minimum member age
    3 monthsInitial authorization for treatment-resistant depression
    1 monthInitial authorization for acute suicidal ideation or behavior
    12 monthsContinuation authorization for treatment-resistant depression

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2 hours
    Post-administration monitoring
    2 classes / 8 weeksTreatment-resistant depression history

    Coverage Criteria

    Initial therapy

    Covered when all common requirements are met and the member meets either the treatment-resistant depression pathway or the major depressive disorder pathway with acute suicidal ideation or behavior.

    Common requirements

    • Diagnosis and administration: Member has a confirmed diagnosis of severe major depressive disorder, single or recurrent episode, documented by standardized rating scales that reliably measure depressive symptoms; member is 18 years of age or older; the requested medication will be administered under the direct supervision of a healthcare provider; and the member will be monitored by a healthcare provider for at least 2 hours after administration.Age >= 18; monitoring >= 2 hours
    • Covered indication pathway

      • Treatment-resistant depression pathway: Member has experienced an inadequate response during the current depressive episode to two antidepressants from at least two different classes with different mechanisms of action, each used at the maximally tolerated labeled dose for at least 8 weeks within the past 5 years; and member has experienced an inadequate response to an adequate trial of augmentation therapy for at least 8 weeks within the past 5 years or has received evidence-based psychotherapy, such as cognitive behavioral therapy, interpersonal therapy, supportive therapy, or psychoeducational intervention, during the current depressive episode.Two antidepressants; at least two classes; each >= 8 weeks within past 5 years; augmentation >= 8 weeks or evidence-based psychotherapy
      • MDD with acute suicidal ideation or behavior pathway: Member has major depressive disorder with current suicidal ideation with intent; the prescriber represents that, in the absence of the requested drug, the member will require confinement in an acute care psychiatric institution within the next 24 to 48 hours; and the requested drug will be used in combination with an oral antidepressant.Acute psychiatric confinement anticipated within 24-48 hours without treatment

    Continuation therapy

    Continuation coverage requires fulfillment of the applicable continuation criteria.

    Continuation pathway

    • Treatment-resistant depression continuation: Member has improvement or sustained improvement from baseline in depressive symptoms documented by standardized rating scales that reliably measure depressive symptoms.Improvement or sustained improvement from baseline

      Continuation authorization may be granted for 12 months.

    • MDD with acute suicidal ideation or behavior continuation: Member continues to meet all requirements in the coverage criteria section.

      Use beyond 4 weeks has not been systematically evaluated for this indication.

    Coverage is not provided for members with moderate or severe substance or alcohol use disorder that is not currently being treated or medically managed.

    Use of Spravato as an anesthetic agent is excluded. Spravato is not approved for this purpose, and its safety and effectiveness as an anesthetic have not been established.

    All indications other than the specified FDA-approved indications are considered experimental, investigational, and not medically necessary.

    Initial Therapy Criteria

    Initial therapy criteria

    Initial coverage requires all common requirements and either the treatment-resistant depression pathway or the MDD with acute suicidal ideation or behavior pathway.

    Initial coverage requirements

    • Indication pathway

      • Treatment-resistant depression: Member has experienced an inadequate response during the current depressive episode to two antidepressants from at least two different classes with different mechanisms of action, each used at the maximally tolerated labeled dose for at least 8 weeks within the past 5 years; and member has experienced an inadequate response to an adequate trial of augmentation therapy for at least 8 weeks within the past 5 years or has received evidence-based psychotherapy during the current depressive episode.Two antidepressants; at least two classes; each >= 8 weeks within past 5 years; augmentation >= 8 weeks or evidence-based psychotherapy
      • MDD with acute suicidal ideation or behavior:

    Continuation Criteria

    Treatment-resistant depression continuation

    Continuation authorization for treatment-resistant depression may be granted for 12 months when the following criterion is met.

    Treatment-resistant depression continuation: Member has improvement or sustained improvement from baseline in depressive symptoms documented by standardized rating scales that reliably measure depressive symptoms.Improvement or sustained improvement from baseline

    Examples of acceptable standardized rating scales include the Beck Depression Inventory, Hamilton Depression Rating Scale, and Montgomery-Asberg Depression Rating Scale.

    MDD acute suicidal ideation continuation

    For major depressive disorder with acute suicidal ideation or behavior, continuation coverage requires the following criterion.

    MDD with acute suicidal ideation or behavior continuation: Member continues to meet all requirements in the coverage criteria section.

    Provider Requirements and Authorization

    Prior Authorization

    Prior Authorization Documentation

    Submit the information required to initiate prior authorization review, including the applicable pretreatment or current depression severity documentation and clinical history supporting the requested use.

    • For initial requests, provide pretreatment depression severity score(s) from a standardized rating scale that reliably measures depressive symptoms, such as BDI, HDRS, or MADRS.
    • For continuation requests, provide current depression severity score(s) from a standardized rating scale, if applicable.
    Documentation Required

    Qualified Prescriber and REMS Setting

    Spravato must be administered by a healthcare provider experienced in treating the member’s disease in a clinical setting that has completed all REMS program requirements.

    • Verify the provider’s relevant treatment experience.

    Policy Background

    Spravato (esketamine) is covered for adults with treatment-resistant depression or depressive symptoms associated with major depressive disorder and acute suicidal ideation or behavior. For the acute suicidal ideation or behavior indication, Spravato is used with an oral antidepressant; its effectiveness in preventing suicide or reducing suicidal ideation or behavior has not been demonstrated, and treatment does not eliminate the need for hospitalization when clinically warranted.

    Definitions

    Current depressive episode
    Applies toTreatment-resistant depression criteria
    Beginning of episodeThe current depressive episode begins with the most recent onset of acute symptoms.
    Use in coverage reviewUse the most recent onset of acute symptoms to identify the current depressive episode.
    Augmentation therapy
    Two antidepressantsTwo antidepressants with different mechanisms of action used concomitantly.
    Second-generation antipsychoticAn antidepressant and a second-generation antipsychotic used concomitantly.
    Lithium

    Step Therapy Requirements

    StepRequirementDetails
    1Two antidepressant trialsInadequate response to two antidepressants from at least two different classes with different mechanisms of action, each used at the maximally tolerated labeled dose for at least 8 weeks within the past 5 years.
    2Augmentation therapy or evidence-based psychotherapyInadequate response to an adequate augmentation-therapy trial for at least 8 weeks within the past 5 years, or evidence-based psychotherapy during the current depressive episode.

    Administration Setting

    Billing Rule

    Use the required site of care and monitoring

    Administer Spravato under the direct supervision of a healthcare provider in a clinical setting that has completed the REMS program requirements. A healthcare provider must monitor the member for at least 2 hours after administration.

    Policy Summary
    PayerCVS Caremark
    PolicySpecialty Guideline Management Spravato
    Policy CodePolicy 2889-A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization requests with the required pretreatment or current standardized depression severity scores.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation CriteriaProvider Requirements and AuthorizationPolicy BackgroundDefinitionsStep Therapy RequirementsAdministration Setting
    Member has major depressive disorder with current suicidal ideation with intent; the prescriber represents that, in the absence of the requested drug, the member will require confinement in an acute care psychiatric institution within the next 24 to 48 hours; and the requested drug will be used in combination with an oral antidepressant.
    Acute psychiatric confinement anticipated within 24-48 hours without treatment

    Use of Spravato beyond 4 weeks has not been systematically evaluated for depressive symptoms in patients with MDD with acute suicidal ideation or behavior.

  1. Verify that the administration site has completed the Spravato REMS requirements.
  2. Prior Authorization

    Initial Authorization Duration

    Authorization may be granted for the specified duration when all applicable coverage criteria are met.

    • Treatment-resistant depression (TRD): authorization may be granted for 3 months.
    • Major depressive disorder (MDD) with acute suicidal ideation or behavior: authorization may be granted for 1 month.
    Documentation Required

    Treatment-Resistant Depression Treatment History

    For TRD, document inadequate response during the current depressive episode to the required antidepressant and augmentation or psychotherapy treatment history.

    • Inadequate response to two antidepressants from at least two different classes with different mechanisms of action, each used at the maximally tolerated labeled dose for at least 8 weeks within the past 5 years.
    • Inadequate response to an adequate trial of augmentation therapy for at least 8 weeks within the past 5 years, or evidence-based psychotherapy during the current depressive episode.
    • Qualifying augmentation may include two antidepressants with different mechanisms used concomitantly, an antidepressant with a second-generation antipsychotic, lithium, or thyroid hormone.
    Documentation Required

    Initial Depression Severity Documentation

    For an initial request, provide pretreatment depression severity score(s) from a standardized rating scale that reliably measures depressive symptoms.

    • Examples include the Beck Depression Inventory (BDI), Hamilton Depression Rating Scale (HDRS), and Montgomery-Asberg Depression Rating Scale (MADRS).
    Documentation Required

    Continuation Depression Severity Documentation

    For continuation of therapy, provide current depression severity score(s) from a standardized rating scale that reliably measures depressive symptoms, if applicable.

    • Use a reliable standardized measure such as BDI, HDRS, or MADRS.
    Denial Risk

    Excluded or Noncovered Use

    Coverage will not be provided for excluded or noncovered uses. Moderate or severe substance or alcohol use disorder must be currently treated or medically managed.

    • All indications other than the FDA-approved indications are experimental/investigational and not medically necessary.
    • Spravato is not approved as an anesthetic agent; safety and effectiveness as an anesthetic have not been established.
    • Effectiveness in preventing suicide or reducing suicidal ideation or behavior has not been demonstrated, and use does not eliminate the need for hospitalization when clinically warranted.
    Denial Risk

    Failure to Meet Administration or Clinical Criteria

    Requests may be denied when required member, administration, monitoring, or clinical criteria are not met.

    • Member must be 18 years of age or older.
    • Administration must occur under the direct supervision of a healthcare provider, with monitoring for at least 2 hours after administration.
    • For TRD, the member must meet the required antidepressant treatment history and augmentation therapy or evidence-based psychotherapy criteria.
    • For MDD with acute suicidal ideation or behavior, the member must have current suicidal ideation with intent, the prescriber must represent that acute psychiatric hospitalization would otherwise be required within 24 to 48 hours, and Spravato must be used with an oral antidepressant.
    Prior Authorization

    REMS and Qualified-Provider Requirement

    Administration must comply with the Spravato REMS and qualified-provider requirements.

    • A qualified, experienced healthcare provider must administer the medication.
    • Administration must occur in a clinical setting that has completed the REMS program requirements.
    • The member must remain under direct supervision and be monitored for at least 2 hours after administration.
    An antidepressant and lithium used concomitantly.
    Thyroid hormoneAn antidepressant and thyroid hormone used concomitantly.
    Current suicidal ideation with intent
    Self-harm thoughtsThoughts, even momentarily, of self-harm with at least some intent or awareness that death may result.
    Suicide thoughtsThinking about suicide qualifies as current suicidal ideation with intent.
    Intent to actThe member intends to act on thoughts of killing themselves.